The LOTIS-7 trial is an ongoing phase I trial testing the safety, efficacy, and tolerability of loncastuximab tesirine (a CD-19 antibody) with glofitamab (a bispecific antibody) in patients with relapsed or refractory DLBCL (NCT04970901). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.